Improved outcomes in children with advanced B-cell non-Hodgkin's lymphoma
Author Information
Author(s): Atra A, Imeson J D, Hobson R, Gerrard M, Hann I M, Eden O B, Carter R L, Pinkerton C R
Primary Institution: Department of Paediatric Oncology, The Royal Marsden Hospital NHS Trust
Hypothesis
Does the UKCCSG 9002 protocol improve outcomes for children with advanced stage B-cell non-Hodgkin's lymphoma?
Conclusion
The study confirms a good prognosis and low rate of toxic deaths in children with advanced B-NHL treated with the UKCCSG 9002 protocol.
Supporting Evidence
- The overall survival rate was 87%.
- Event-free survival was 83.7%.
- Only 5.4% of patients never achieved complete remission.
- There were three early toxic deaths mainly from infection.
Takeaway
This study shows that kids with a serious type of cancer can do well with a specific treatment plan.
Methodology
Children with advanced B-NHL were treated according to the UKCCSG 9002 protocol, and their outcomes were analyzed over a median follow-up of 48 months.
Limitations
The study did not identify a subgroup of patients who could avoid intensive therapy.
Participant Demographics
The median age of participants was 8.3 years, with 81 boys and 31 girls.
Statistical Information
Confidence Interval
EFS 83.7% (95% CI 76.3–89.2%)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website